{"id":151374,"date":"2026-07-15T09:55:32","date_gmt":"2026-07-15T04:25:32","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=151374"},"modified":"2026-07-15T09:55:33","modified_gmt":"2026-07-15T04:25:33","slug":"alivus-life-sciences-share-price-forecast-next-3-years","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/","title":{"rendered":"Alivus Life Sciences Share Price: What Could the Next 3 Years Look Like?"},"content":{"rendered":"<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Alivus Life Sciences share price Rs 1,169. 52W high Rs 1,194, low Rs 819. Market cap Rs 14,354 Cr. 2030 scenario range Rs 1,280 to Rs 2,110.<\/em><\/p>\n<p>The <a href=\"https:\/\/univest.in\/stocks\/alivus\/glenmark-life-sciences-ltd-share-price-today\">Alivus Life Sciences<\/a> share price forecast for the next 3 years is a question on many investors&#8217; minds as the stock trades at Rs 1,169, within a 52 week range of Rs 819 to Rs 1,194. This article lays out a scenario based Alivus Life Sciences share price outlook for 2027, 2028 and 2030, built on the company&#8217;s fundamentals, sector trends and the key risks that could change the trajectory. Rather than a single number, the focus here is on the range of outcomes and the assumptions behind each one.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=alivus-life-sciences-forecast-3yr\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#Alivus_Life_Sciences_Company_Overview\" title=\"Alivus Life Sciences Company Overview\">Alivus Life Sciences Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#Where_Does_Alivus_Life_Sciences_Share_Price_Stand_Today\" title=\"Where Does Alivus Life Sciences Share Price Stand Today?\">Where Does Alivus Life Sciences Share Price Stand Today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#Alivus_Life_Sciences_Share_Price_Forecast_Key_Growth_Drivers_for_the_Next_3_Years\" title=\"Alivus Life Sciences Share Price Forecast: Key Growth Drivers for the Next 3 Years\">Alivus Life Sciences Share Price Forecast: Key Growth Drivers for the Next 3 Years<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#Earnings_Trajectory_and_Return_Ratios\" title=\"Earnings Trajectory and Return Ratios\">Earnings Trajectory and Return Ratios<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#Structural_Tailwinds_in_Indian_Pharmaceuticals\" title=\"Structural Tailwinds in Indian Pharmaceuticals\">Structural Tailwinds in Indian Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#Company_Specific_Catalysts\" title=\"Company Specific Catalysts\">Company Specific Catalysts<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#Macro_Environment_and_Liquidity\" title=\"Macro Environment and Liquidity\">Macro Environment and Liquidity<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#Alivus_Life_Sciences_Share_Price_Forecast_2027_2028_and_2030_Scenario_Analysis\" title=\"Alivus Life Sciences Share Price Forecast 2027, 2028 and 2030: Scenario Analysis\">Alivus Life Sciences Share Price Forecast 2027, 2028 and 2030: Scenario Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#Bull_Case_vs_Bear_Case_for_Alivus_Life_Sciences_Share_Price\" title=\"Bull Case vs Bear Case for Alivus Life Sciences Share Price\">Bull Case vs Bear Case for Alivus Life Sciences Share Price<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#The_Bull_Case\" title=\"The Bull Case\">The Bull Case<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#The_Bear_Case\" title=\"The Bear Case\">The Bear Case<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#Key_Risks_That_Could_Change_the_Alivus_Life_Sciences_Share_Price_Outlook\" title=\"Key Risks That Could Change the Alivus Life Sciences Share Price Outlook\">Key Risks That Could Change the Alivus Life Sciences Share Price Outlook<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#Is_Alivus_Life_Sciences_Worth_Watching_for_the_Long_Term\" title=\"Is Alivus Life Sciences Worth Watching for the Long Term?\">Is Alivus Life Sciences Worth Watching for the Long Term?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#What_is_the_Alivus_Life_Sciences_share_price_forecast_for_the_next_3_years\" title=\"What is the Alivus Life Sciences share price forecast for the next 3 years?\">What is the Alivus Life Sciences share price forecast for the next 3 years?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#What_is_the_Alivus_Life_Sciences_share_price_forecast_for_2027\" title=\"What is the Alivus Life Sciences share price forecast for 2027?\">What is the Alivus Life Sciences share price forecast for 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#What_is_the_Alivus_Life_Sciences_share_price_forecast_for_2028\" title=\"What is the Alivus Life Sciences share price forecast for 2028?\">What is the Alivus Life Sciences share price forecast for 2028?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#What_is_the_current_share_price_of_Alivus_Life_Sciences\" title=\"What is the current share price of Alivus Life Sciences?\">What is the current share price of Alivus Life Sciences?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#Is_Alivus_Life_Sciences_a_good_stock_for_the_long_term\" title=\"Is Alivus Life Sciences a good stock for the long term?\">Is Alivus Life Sciences a good stock for the long term?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#What_is_the_Alivus_Life_Sciences_share_price_outlook_for_2030\" title=\"What is the Alivus Life Sciences share price outlook for 2030?\">What is the Alivus Life Sciences share price outlook for 2030?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/alivus-life-sciences-share-price-forecast-next-3-years\/#What_are_the_key_risks_to_the_Alivus_Life_Sciences_share_price_forecast\" title=\"What are the key risks to the Alivus Life Sciences share price forecast?\">What are the key risks to the Alivus Life Sciences share price forecast?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Alivus_Life_Sciences_Company_Overview\"><\/span><strong>Alivus Life Sciences Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Alivus Life Sciences, formerly Glenmark Life Sciences, is a leading manufacturer of active pharmaceutical ingredients serving generic drug makers globally, now under Nirma Group ownership after the 2023 acquisition. Understanding the business model is the first step in framing any credible Alivus Life Sciences share price forecast, because the durability of earnings ultimately decides where the stock trades.<\/p>\n<table>\n<tbody>\n<tr>\n<td><strong>Company<\/strong><\/td>\n<td><a href=\"https:\/\/univest.in\/stocks\/alivus\/glenmark-life-sciences-ltd-share-price-today\">Alivus Life Sciences<\/a><\/td>\n<\/tr>\n<tr>\n<td><strong>NSE Ticker<\/strong><\/td>\n<td>ALIVUS<\/td>\n<\/tr>\n<tr>\n<td><strong>CMP<\/strong><\/td>\n<td>Rs 1,169<\/td>\n<\/tr>\n<tr>\n<td><strong>52 Week High<\/strong><\/td>\n<td>Rs 1,194<\/td>\n<\/tr>\n<tr>\n<td><strong>52 Week Low<\/strong><\/td>\n<td>Rs 819<\/td>\n<\/tr>\n<tr>\n<td><strong>Market Cap<\/strong><\/td>\n<td>Rs 14,354 Cr<\/td>\n<\/tr>\n<tr>\n<td><strong>Stock PE<\/strong><\/td>\n<td>40.8<\/td>\n<\/tr>\n<tr>\n<td><strong>Book Value<\/strong><\/td>\n<td>Rs NA<\/td>\n<\/tr>\n<tr>\n<td><strong>ROE<\/strong><\/td>\n<td>NA<\/td>\n<\/tr>\n<tr>\n<td><strong>ROCE<\/strong><\/td>\n<td>NA<\/td>\n<\/tr>\n<tr>\n<td><strong>Dividend Yield<\/strong><\/td>\n<td>0.43%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Where_Does_Alivus_Life_Sciences_Share_Price_Stand_Today\"><\/span><strong>Where Does Alivus Life Sciences Share Price Stand Today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The stock trades close to its 52 week high of Rs 1,194, indicating strong recent momentum. A Alivus Life Sciences share price forecast built from these levels must assume earnings keep pace with expectations, and the Alivus Life Sciences share price forecast becomes more sensitive to disappointments, since elevated starting valuations can cap medium term returns.<\/p>\n<p>At the current price, Alivus Life Sciences commands a market capitalisation of Rs 14,354 Cr and trades at a price to earnings multiple of 40.8. The company generates a return on equity of NA and a return on capital employed of NA, which places it in the category of businesses with a recovering profitability profile. These numbers anchor the Alivus Life Sciences share price forecast scenarios that follow. How the broader <a href=\"https:\/\/univest.in\/indices\/nifty-50\/nifty-50-share-price-today\">Nifty 50<\/a> index trades over this period will also influence the multiple investors are willing to assign to the stock.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Alivus_Life_Sciences_Share_Price_Forecast_Key_Growth_Drivers_for_the_Next_3_Years\"><\/span><strong>Alivus Life Sciences Share Price Forecast: Key Growth Drivers for the Next 3 Years<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Four forces are likely to shape the Alivus Life Sciences share price forecast between now and 2030, and together they explain most of the dispersion in this Alivus Life Sciences share price forecast. Each is discussed below with its likely direction of impact.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Earnings_Trajectory_and_Return_Ratios\"><\/span><strong>Earnings Trajectory and Return Ratios<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Stock prices ultimately follow earnings. With a recovering profitability profile at present, the pace at which profits compound over FY27 to FY30 will be the single biggest determinant of the Alivus Life Sciences share price forecast actually playing out. Consistent earnings delivery tends to expand valuation multiples, while misses compress them quickly.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Structural_Tailwinds_in_Indian_Pharmaceuticals\"><\/span><strong>Structural Tailwinds in Indian Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Indian pharmaceutical market continues to grow in high single to low double digits, supported by chronic disease prevalence, better diagnosis rates and premiumisation of therapies. Companies with strong brand equity and field force productivity, like Alivus Life Sciences, are positioned to grow ahead of the market. Sector trends are visible in the <a href=\"https:\/\/univest.in\/indices\/nifty-pharma\/nifty-pharma-share-price-today\">Nifty Pharma<\/a> index, which serves as a useful barometer for the space.<\/p>\n<p>Within the space, investors often benchmark Alivus Life Sciences against peers such as <a href=\"https:\/\/univest.in\/stocks\/divislab\/divi's-laboratories-ltd-share-price-today\">Divis Laboratories<\/a>, <a href=\"https:\/\/univest.in\/stocks\/lauruslabs\/laurus-labs-ltd-share-price-today\">Laurus Labs<\/a> and <a href=\"https:\/\/univest.in\/stocks\/aartipharm\/aarti-pharmalabs-ltd-share-price-today\">Aarti Pharmalabs<\/a> on growth and valuations before forming a view on the Alivus Life Sciences share price forecast.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Company_Specific_Catalysts\"><\/span><strong>Company Specific Catalysts<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bull case for Alivus Life Sciences rests on rising global API demand, new molecule additions and margin improvement under new ownership. If these play out on schedule, the Alivus Life Sciences share price forecast for 2030 could gravitate toward the upper end of the scenario range discussed below.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Macro_Environment_and_Liquidity\"><\/span><strong>Macro Environment and Liquidity<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The RBI rate cycle, FII flows into Indian equities and overall market valuations will influence the multiple investors are willing to pay. A benign macro backdrop supports the optimistic end of any Alivus Life Sciences share price forecast, while global risk aversion would do the opposite to the Alivus Life Sciences share price outlook.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Alivus_Life_Sciences_Share_Price_Forecast_2027_2028_and_2030_Scenario_Analysis\"><\/span><strong>Alivus Life Sciences Share Price Forecast 2027, 2028 and 2030: Scenario Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below presents a scenario based Alivus Life Sciences share price forecast using compounded annual growth assumptions applied to the current market price of Rs 1,169. These are illustrative ranges, not point predictions, and actual outcomes can fall outside them.<\/p>\n<table>\n<thead>\n<tr>\n<th>Year<\/th>\n<th>Bear Case<\/th>\n<th>Base Case<\/th>\n<th>Bull Case<\/th>\n<th>Assumption<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>2027<\/td>\n<td>Rs 1,200<\/td>\n<td>Rs 1,310<\/td>\n<td>Rs 1,420<\/td>\n<td>2% to 14% CAGR on CMP<\/td>\n<\/tr>\n<tr>\n<td>2028<\/td>\n<td>Rs 1,230<\/td>\n<td>Rs 1,420<\/td>\n<td>Rs 1,620<\/td>\n<td>2% to 14% CAGR on CMP<\/td>\n<\/tr>\n<tr>\n<td>2030<\/td>\n<td>Rs 1,280<\/td>\n<td>Rs 1,650<\/td>\n<td>Rs 2,110<\/td>\n<td>2% to 14% CAGR on CMP<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>In the base case scenario of this Alivus Life Sciences share price forecast, the 2030 level works out to roughly Rs 1,650, implying steady compounding from today&#8217;s levels. The bull case of Rs 2,110 assumes rising global API demand delivers ahead of expectations, while the bear case of Rs 1,280 captures a scenario where growth stalls. That is an outcome band of about 9 percent to 80 percent over the period.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/sebi-registered-investment-advisor-india\"><strong>Consult a SEBI Registered Investment Advisor Before Acting on Any Forecast<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_vs_Bear_Case_for_Alivus_Life_Sciences_Share_Price\"><\/span><strong>Bull Case vs Bear Case for Alivus Life Sciences Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"The_Bull_Case\"><\/span><strong>The Bull Case<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The optimistic Alivus Life Sciences share price forecast assumes rising global API demand, new molecule additions and margin improvement under new ownership. Combined with supportive sector conditions, this could lift both earnings and the valuation multiple, pushing the stock toward Rs 2,110 by 2030.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"The_Bear_Case\"><\/span><strong>The Bear Case<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The cautious view centres on the fact that API pricing is competitive globally and client concentration among a few large generic makers is a risk. If these pressures dominate, the Alivus Life Sciences share price forecast would skew toward the lower band and the stock could stagnate near Rs 1,280 even by 2030, underperforming broader indices.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_That_Could_Change_the_Alivus_Life_Sciences_Share_Price_Outlook\"><\/span><strong>Key Risks That Could Change the Alivus Life Sciences Share Price Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Execution risk:<\/strong> Delays in strategy execution or capacity plans would push the earnings trajectory below the base case assumed in this Alivus Life Sciences share price forecast.<\/li>\n<li><strong>Valuation risk:<\/strong> At a PE of 40.8, any earnings disappointment can trigger sharp multiple compression before fundamentals stabilise.<\/li>\n<li><strong>Sector risk:<\/strong> API pricing is competitive globally and client concentration among a few large generic makers is a risk.<\/li>\n<li><strong>Macro risk:<\/strong> A global slowdown, adverse FII flows or unexpected rate moves would compress equity valuations across the market.<\/li>\n<li><strong>Regulatory risk:<\/strong> Policy, tax or compliance changes affecting the sector can alter the earnings outlook with little warning.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Is_Alivus_Life_Sciences_Worth_Watching_for_the_Long_Term\"><\/span><strong>Is Alivus Life Sciences Worth Watching for the Long Term?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>For long term investors, the relevant question is not just where the Alivus Life Sciences share price forecast lands in 2030 or what any single Alivus Life Sciences share price forecast says today, but whether the business can compound capital through cycles. The company&#8217;s positioning around rising global API demand gives it a credible growth story, while the risks outlined above define what must be monitored each quarter.<\/p>\n<p>Investors should track quarterly earnings, management commentary and sector data rather than anchoring to any single number from a Alivus Life Sciences share price outlook. Historically, staying focused on business fundamentals has served investors better than chasing price targets, and consulting a SEBI registered advisor before investing remains the prudent approach.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Alivus Life Sciences share price live.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Alivus Life Sciences share price forecast for the next 3 years spans Rs 1,280 to Rs 2,110 by 2030 under the scenarios discussed, with a base case near Rs 1,650. Any credible Alivus Life Sciences share price forecast must be updated as facts change, and the path will be decided by earnings delivery, rising global API demand and the broader market environment. Treat these ranges as a framework for thinking, not a promise of outcomes, and revisit the assumptions as new results come in. Consult a SEBI registered investment advisor before making any investment decision.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Alivus_Life_Sciences_share_price_forecast_for_the_next_3_years\"><\/span><strong>What is the Alivus Life Sciences share price forecast for the next 3 years?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Alivus Life Sciences share price forecast for the next 3 years is scenario based rather than a single number. By 2030, the illustrative range spans Rs 1,280 in the bear case to Rs 2,110 in the bull case, with a base case near Rs 1,650, depending on earnings delivery and market conditions.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Alivus_Life_Sciences_share_price_forecast_for_2027\"><\/span><strong>What is the Alivus Life Sciences share price forecast for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> For 2027, the scenario range works out to Rs 1,200 to Rs 1,420, with a base case around Rs 1,310. This assumes compounding on the current price of Rs 1,169 and is illustrative, not a guaranteed outcome.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Alivus_Life_Sciences_share_price_forecast_for_2028\"><\/span><strong>What is the Alivus Life Sciences share price forecast for 2028?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The 2028 scenario range is Rs 1,230 to Rs 1,620, with the base case near Rs 1,420. Actual levels will depend on earnings growth, sector trends and overall market valuations at the time.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_current_share_price_of_Alivus_Life_Sciences\"><\/span><strong>What is the current share price of Alivus Life Sciences?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alivus Life Sciences currently trades at around Rs 1,169 on the NSE, within a 52 week range of Rs 819 to Rs 1,194. Prices change continuously during market hours, so check live quotes before acting.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Alivus_Life_Sciences_a_good_stock_for_the_long_term\"><\/span><strong>Is Alivus Life Sciences a good stock for the long term?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alivus Life Sciences has a credible long term story built on rising global API demand, but it also carries risks since API pricing is competitive globally and client concentration among a few large generic makers is a risk. Long term suitability depends on your risk profile and portfolio, so consult a SEBI registered investment advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Alivus_Life_Sciences_share_price_outlook_for_2030\"><\/span><strong>What is the Alivus Life Sciences share price outlook for 2030?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Alivus Life Sciences share price outlook for 2030 spans Rs 1,280 to Rs 2,110 across bear and bull scenarios. Where the stock actually lands will be driven by profit growth, valuation multiples and macro conditions closer to that date.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_to_the_Alivus_Life_Sciences_share_price_forecast\"><\/span><strong>What are the key risks to the Alivus Life Sciences share price forecast?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The main risks are execution delays, valuation compression from the current PE of 40.8, sector specific pressures, macro shocks and regulatory changes. Any of these can push the stock below the base case scenario discussed in this article.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Alivus Life Sciences share price forecast for the next 3 years points to a scenario range of Rs 1,280 to Rs 2,110 by 2030, driven by rising global API demand and sector tailwinds.<\/p>\n","protected":false},"author":34,"featured_media":151827,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-151374","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1784089536:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_title":["Alivus Life Sciences Share Price Forecast: 3 Year Outlook to 2030"],"rank_math_description":["Where will Alivus Life Sciences share price be in the next 3 years? Detailed Alivus Life Sciences share price forecast with 2027, 2028 and 2030 scenarios, growth drivers and risks."],"rank_math_focus_keyword":["Alivus Life Sciences share price forecast"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_wp_old_date":["2026-07-14"],"_thumbnail_id":["151827"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["26315"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/07\/Alivus-Life-Sciences-Share-Price.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/151374","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=151374"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/151374\/revisions"}],"predecessor-version":[{"id":151828,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/151374\/revisions\/151828"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/151827"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=151374"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=151374"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=151374"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}